Grzegorz Korpanty

Summary

Publications

  1. pmc Molecular and clinical aspects of targeting the VEGF pathway in tumors
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland
    J Oncol 2010:652320. 2010
  2. ncbi request reprint Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer
    Grzegorz Korpanty
    Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
    Curr Pharm Des 18:2680-701. 2012
  3. pmc Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland
    Exp Biol Med (Maywood) 235:3-9. 2010
  4. doi request reprint Phyllodes tumor of the breast
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
    Med Oncol 28:S62-4. 2011
  5. pmc Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
    J Thorac Dis 3:19-29. 2011

Collaborators

Detail Information

Publications5

  1. pmc Molecular and clinical aspects of targeting the VEGF pathway in tumors
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland
    J Oncol 2010:652320. 2010
    ..In addition, the development of reliable tools to track tumor responses to antiangiogenic therapy will enable a better understanding of current therapeutic efficacy and may elucidate mechanisms to predict patient response to therapy...
  2. ncbi request reprint Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer
    Grzegorz Korpanty
    Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland
    Curr Pharm Des 18:2680-701. 2012
    ..In 2012, both monoclonal antibodies and small molecule tyrosine kinase inhibitors remain the two major clinically useful therapeutic options that interfere with tumour angiogenesis in many solid malignancies...
  3. pmc Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland
    Exp Biol Med (Maywood) 235:3-9. 2010
    ..In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant...
  4. doi request reprint Phyllodes tumor of the breast
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
    Med Oncol 28:S62-4. 2011
    ..She was diagnosed with phyllodes tumor of her breast and treated initially with neoadjuvant chemotherapy and mastectomy. We discuss recent advances in diagnosis and management of breast phyllodes tumors...
  5. pmc Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?
    Grzegorz Korpanty
    Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
    J Thorac Dis 3:19-29. 2011
    ..In this review we will briefly discuss briefly the basic mechanisms of lung cancer angiogenesis, rationale for using drugs that block this process and present the most current recent data on their clinical efficacy...